GC Wellbeing Confirms Protective Effect of "Laennec" Against Alcoholic Fatty Liver

Non-Clinical Study Shows Reduction of Hepatic Fat Accumulation and Tissue Damage

GC Wellbeing announced on August 19 that non-clinical study results confirming the protective effect of its placenta injection agent "Laennec" against alcoholic fatty liver have been published in the international journal "Current Issues In Molecular Biology (CIMB)."

This study, conducted in collaboration with Professor Kang Juseop's team at Hanyang University College of Medicine, elucidated that Laennec inhibits hepatic fat accumulation and alleviates oxidative stress in a model of alcohol-induced fatty liver.

The research team induced fatty liver in animal models using a liquid diet containing alcohol, then administered intravenous Laennec twice a week. They then comprehensively analyzed various factors, including blood markers for liver function, hepatic fat accumulation and inflammation, alcohol-metabolizing enzymes, antioxidant enzymes, and signal transduction pathways related to hepatocyte protection.

The results showed that serum ALT, a liver injury marker sharply elevated by alcohol intake, was significantly reduced depending on the administered dose of Laennec. In liver tissue analyses, both fat accumulation and the spread of inflammatory cells were noticeably alleviated.

In particular, Laennec exhibited multiple protective actions on the liver: It inhibited the activity of CYP2E1, a factor responsible for the production of reactive oxygen species that cause liver damage during alcohol metabolism, and at the same time activated STAT3, a protein that promotes the regeneration of damaged hepatocytes.

The researchers concluded that Laennec displayed a comprehensive protective effect on the liver by alleviating oxidative stress caused by alcohol metabolism and restoring the antioxidant defense system in liver cells.

Previously, GC Wellbeing confirmed in a phase 3 clinical trial involving 226 domestic patients with chronic liver disease that the high-dose intravenous drip group of Laennec showed statistically significant results in improving liver function compared to the conventional subcutaneous injection group.

GC Wellbeing plans to apply to the Ministry of Food and Drug Safety within this year for a product license variation to add the intravenous administration method.

Jung Siyoung, Head of R&D at GC Wellbeing, commented, "This study provides important academic evidence supporting the efficacy of intravenous administration of Laennec. Based on the pharmacological mechanisms demonstrated in the non-clinical study and the results of phase 3 clinical trials, we will expedite the approval process for expanding its intravenous use."

This content was produced with the assistance of AI translation services.